NEW YORK, Dec. 10, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liberator Medical Holdings, Inc. ("Liberator Medical" or the "Company") (NYSE: LBMH) (ISIN: US5312L1089) (CUSIP: 5312L108) concerning the proposed acquisition of Liberator by C.R. Bard, Inc.
Liberator Medical shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at firstname.lastname@example.org or 212-661-1100 or 888-476-6529, ext. 9980.
The investigation concerns whether the Liberator Medical directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the proposed transaction, Liberator Medical shareholders will receive $3.35 per shares in cash for each Liberator Medical share. However, an analyst recently set a price target of $8.00 per share for Liberator Medical, additionally, EBITDA, EBIT, and Total Revenue are below the averages of comparable transactions, according to a Bloomberg analysis.
Pomerantz LLP, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz LLP pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz LLP continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
CONTACT: Robert Willoughby Pomerantz LLP 212-661-1100 ext. 9980 email@example.com
SOURCE Pomerantz LLP